Unlocking the Immune System to Attack Cancer    

Neon Therapeutics is an immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer. A neoantigen-based product engine will allow Neon to develop further treatment modalities including next-generation vaccines and T cell therapies targeting both personalized as well as shared neoantigens. Neon Therapeutics’ lead program is a personalized neoantigen vaccine that builds upon years of research and development at the Broad Institute and Dana-Farber Cancer Institute, and is already in multiple clinical trials.

Year Invested: 2015
Location: Cambridge, Mass.
Visit: neontherapeutics.com

Recent News

February 21, 2017
Using Mono-allelic Mass Spectrometry Data to Improve Epitope Prediction Algorithms Published in Immunity

January 5, 2017
Neon Therapeutics Secures $70 Million in Series B Financing

December 28, 2016
Neon Therapeutics to Present at 35th Annual J.P. Morgan Healthcare Conference

Read More News

Associated Team Members

Cary Pfeffer, M.D.

Robert Tepper, M.D.

Robert Kamen, Ph.D.

Stephen Sherwin, M.D.
Venture Partner